The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma

Pharmacogenetics and Genomics

Volumn 22, Issue 1, 2012, Pages 58-68

  Erčulj, Nina ^a   Kovač, Viljem ^b   Hmeljak, Julija ^c   Franko, Alenka ^b   Dodič Fikfak, Metoda ^b   Dolžan, Vita ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY OF PRIMORSKA   (Slovenia)

Author keywords

gemcitabine pathway; malignant mesothelioma; single nucleotide polymorphism; toxicity; treatment outcome

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; LEUKOPENIA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PLEURECTOMY; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 83655164249     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834e3572     Document Type: Article

References (54)

1. Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 2010; 5:1841-1848.
2. Kovac V, Debevec M, Plaper-Vernik M, Debeljak A, Erzen J, Remskar Z, et al. Malignant pleural mesothelioma (MPM) in Slovenia, 1980-1997. Lung Cancer 2001; 32:S57(abstract).
3. Steele JP. Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 2005; 19:1041-1052. (Pubitemid 41736041)
4. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988; 41:525-530.
5. Curran D, Sahmoud T, Therasse P, Van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16:145-152. (Pubitemid 28041592)
6. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, De Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2009; 35:479-495.
7. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27:3007-3013.
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644. (Pubitemid 46606305)
9. Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with firstline platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 2009; 64:308-313.
10. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004; 95:753-757. (Pubitemid 39335096)
11. Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, et al. Development and molecular characterization of a 20,20- difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 1994; 54:4138-4143.
12. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10:1318-1325. (Pubitemid 38365223)
13. Kroep JR, Loves WJ, Van der Wilt CL, Alvarez E, Talianidis I, Boven E, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002; 1:371-376.
14. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003; 22:3548-3553. (Pubitemid 36765314)
15. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Cellular elimination of 20,20-difluorodeoxycytidine 50-triphosphate: a mechanism of self-potentiation. Cancer Res 1992; 52:533-539.
16. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17 (Suppl 5):v7-v12. (Pubitemid 43994854)
17. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66:3928-3935.
18. Myers SN, Goyal RK, Roy JD, Fairfull LD,Wilson JW, Ferrell RE. Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet Genomics 2006; 16:315-320.
19. Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007; 323:935-945. (Pubitemid 350146062)
20. Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G, et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004; 14:759-768. (Pubitemid 39552791)
21. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007; 96:457-463. (Pubitemid 46215217)
22. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64:3761-3766. (Pubitemid 38697284)
23. Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005; 47: 183-192. (Pubitemid 40082161)
24. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, et al. Ribonucleotide reductase M1 (RRM1) 2464GA polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 2006; 16:429-438. (Pubitemid 43804800)
25. Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS, et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008; 14:3083-3088.
26. Seve P, Mackey JR, Isaac S, Tredan O, Souquet PJ, Perol M, et al. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 2005; 49:363-370. (Pubitemid 41139149)
27. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996; 24: 1340-1346. (Pubitemid 26348932)
28. Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S, et al. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 2009; 100:870-873.
29. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25: 32-42. (Pubitemid 350003048)
30. Aksoy P, Zhu MJ, Kalari KR, Moon I, Pelleymounter LL, Eckloff BW, et al. Cytosolic 50-nucleotidase III (NT5C3): gene sequence variation and functional genomics. Pharmacogenet Genomics 2009; 19:567-576.
31. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006; 12:1794-1803.
32. Kovac V, Zwitter M, Smrdel U, Debeljak A, Cesar R, Kern I. Low-dose gemcitabine in prolonged infusion and cisplatin for malignant pleural mesothelioma: a phase I-II trials. Lung Cancer 2004; 45:S68(abstract).
33. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15:257-260. (Pubitemid 38262625)
34. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29:308-311. (Pubitemid 32054478)
35. Consortium IH. The international HapMap project. Nature 2003; 426: 789-796.
36. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37:W600-W605.
37. Barenboim M, Zoltick BJ, Guo Y,Weinberger DR. MicroSNiPer: a web tool for prediction of SNP effects on putative microRNA targets. Hum Mutat 2010; 31:1223-1232.
38. Bao L, Zhou M, Wu L, Lu L, Goldowitz D, Williams RW, et al. PolymiRTS Database: linking polymorphisms in microRNA target sites with complex traits. Nucleic Acids Res 2007; 35:D51-D54. (Pubitemid 46056169)
39. Xu Z, Kaplan NL, Taylor JA. TAGster: efficient selection of LD tag SNPs in single or multiple populations. Bioinformatics 2007; 23: 3254-3255. (Pubitemid 350187533)
40. Hmeljak J, Kern I, Cor A. No implication of Simian virus 40 in pathogenesis of malignant pleural mesothelioma in Slovenia. Tumori 2010; 96:667-673.
41. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23:1038-1039. (Pubitemid 47050595)
42. Yue L, Saikawa Y, Ota K, Tanaka M, Nishimura R, Uehara T, et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003; 13:29-38. (Pubitemid 36135684)
43. Rodriguez J, Boni V, Hernandez A, Bitarte N, Zarate R, Ponz-Sarvise M, et al. Association of RRM1-37A C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy. Eur J Cancer 2011; 47:839-847.
44. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2009; 16:320-329.
45. Grau JJ, Caballero M, Monzo M, Munoz-Garcia C, Domingo-Domenech J, Navarro A, et al. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J Surg Oncol 2008; 98:130-134.
46. Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, et al. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2011 doi: 10.1007/s00280-00011-01670-00284 (in press).
47. Tanrikulu AC, Abakay A, Kaplan MA, Kucukoner M, Palanci Y, Evliyaoglu O, et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration 2010; 80:480-487.
48. Nojiri S, Gemba K, Aoe K, Kato K, Yamaguchi T, Sato T, et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 2011; 41:32-39.
49. Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T, et al. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol 2011; 18:2381-2387.
50. Feng JF,Wu JZ, Hu SN, Gao CM, Shi MQ, Lu ZH, et al. Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer. Lung Cancer 2009; 66:344-349.
51. De las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17:668-675.
52. Rha SY, Jeung HC, Choi YH, Yang WI, Yoo JH, Kim BS, et al. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist 2007; 12:622-630.
53. Vidan-Jeras B, Jurca B, Dolzan V, Jeras M, Breskvar K, Bohinjec M. Slovenian Caucasian normal. In: Terasaki PI, Gjerston DW, editors. HLA 1998. Edition Lenexa: American Society for Histocompatibility and Immunogenetics; 1998. pp. 180-181.
54. Marsh ER, Vigliano VC,Weiss JR, Moerlein AW, Vallance RR. Precision instrumentation for rolling element bearing characterization. Rev Sci Instrum 2007; 78:035113.